Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Jun 13, 2021 9:47pm
263 Views
Post# 33380045

RE:RE:RE:RE:From the April Newsletter

RE:RE:RE:RE:From the April NewsletterTheralase announced it had been granted Fast Track Designation on Nov. 23, 2020, almost 7 months ago. It issued the newsletter advising us of their intention to submit 450 day data for the first 25 patients, on April 27, just 47 days ago. I emailed Theralase for clarification of their statement in the newsletter. I'll post their reply if I get one.

Yajne wrote: I'm having trouble accepting that they'll be required to wait until P25 has hit 360 or even 450 days. Hopefully TLT is taking advantage of their ongoing communication access gained with Fast Track Approval to share data at earlier milestones and maybe they don't have to wait until P25 hits 360.


Eoganacht wrote: Except that Theralase announced in the newsletter it would be compiling 450 day data on the first 20 - 25 patients. 450 days is exactly 90 days after 360 days so it sounds to me like Theralase is saying the submission will occur 360 days after the first 90 day assessment of patient 25, or 450 days after the initial treatment of patient 25.

Johnandrose22 wrote: I would think that Phase 1 patients 5 and 6 would cover the long range of this interim data, ie 450 days. Perhaps that is why the company highlighted their extraordinary CRs in consistent news releases.

Good news continues to build.

John

 




<< Previous
Bullboard Posts
Next >>